Biomarker
Body Composition (Fat Mass, Lean Mass, Visceral Fat)
The muscle-to-fat and fat-distribution profile of the body, where the combination of low muscle mass and high visceral fat (sarcopenic obesity) carries dramatically higher mortality risk than either alone.
Summary What does body composition reveal about health beyond weight and BMI? Show / hide ↓
Body composition shows how much of your body is fat, muscle, and bone, and where that fat is stored. Sarcopenia means unusually low muscle mass, while visceral fat means fat around the organs; having both is called sarcopenic obesity. In one study of older adults with heart disease, sarcopenia alone was linked to 1.93 times the risk of a major health event, compared with 6.74 times the risk when high visceral fat was also present. Another study found that each extra 100 grams of visceral fat nearly doubled men’s odds of dying, while low muscle mass was a particularly strong risk marker in women. Scans such as DXA can measure body composition, but the evidence is mainly observational and the definitions and measurement methods differ between studies.
What this means for you: Muscle mass and fat location may matter more than body weight alone, but the exact level of risk is still uncertain. Resistance training and enough protein are better-supported ways to protect muscle than dieting alone.
weak evidenceBody composition, the proportion and distribution of fat mass, lean muscle mass, and bone mass in the body, provides a far more health-relevant picture than body weight or BMI alone, since two people with identical BMI can have very different metabolic risk depending on how much of that weight is muscle versus visceral fat. The claim: the combination of low muscle mass (sarcopenia) and high visceral or abdominal fat, sometimes called sarcopenic obesity, carries dramatically higher mortality and cardiovascular risk than either condition alone.
A 2025 study of older adults with cardiovascular disease found sarcopenia alone was associated with a 1.93-fold increased risk of the composite primary outcome (95% CI 1.02-3.66), but this risk jumped to 6.74-fold (95% CI 1.81-25.16) in patients with sarcopenic obesity, driven substantially by all-cause mortality that was 8.48 times higher in sarcopenic patients compared with non-sarcopenic patients (56.3 vs. 6.9 deaths per 1,000 person-years) [1]. A Brazilian population-based cohort of community-dwelling older adults found that in men, each 100-gram increase in visceral fat mass raised all-cause mortality odds by 99% (odds ratio 1.99, 95% CI 1.38-2.87) after adjustment for BMI, smoking, and other risk factors, while fat mass index was actually associated with lower mortality risk once sarcopenia and visceral fat were accounted for separately, illustrating that it is fat distribution and lean mass, not total fat mass, that carries the risk signal [2]. In women in the same cohort, sarcopenia alone was an extremely strong predictor of both all-cause (odds ratio 62.88) and cardiovascular mortality (odds ratio 74.54), far exceeding the male-specific effect sizes, indicating substantial sex differences in how body composition translates to mortality risk [2]. An umbrella review of systematic reviews found sarcopenic obesity increased cardiovascular mortality risk (hazard ratio 1.63, 95% CI 1.01-2.62) though the certainty of evidence was rated very low due to inconsistency across studies [3].
How to measure it: dual-energy X-ray absorptiometry (DXA) is the clinical reference standard, providing separate measurements of fat mass, lean mass, and bone mineral density along with regional distribution, though DXA visceral fat estimates are less precise than CT or MRI [4]. Bioelectrical impedance analysis (BIA) offers a cheaper, more accessible but less accurate alternative common in consumer scales and clinics [5].
How to intervene on it: resistance training combined with adequate protein intake is the best-supported intervention for preserving or building lean muscle mass while losing fat, and is specifically recommended over pure caloric restriction alone in older adults, since weight loss without resistance exercise disproportionately reduces muscle mass alongside fat mass, worsening the sarcopenic-obesity risk profile rather than improving it.
Critics note that most body-composition mortality studies are observational and vary widely in sarcopenia and obesity definitions used across studies, contributing to the very-low-certainty grading in systematic review evidence [3]; measurement method also matters substantially, since DXA, BIA, and CT/MRI visceral fat estimates do not always agree closely with each other, complicating comparison across the literature [5].
Bryan Johnson's Blueprint protocol tracks DXA-measured body fat percentage and lean mass as routine panel items, an n=1 self-report rather than trial evidence [6].
The plain takeaway: total body weight and BMI obscure a health-relevant distinction between muscle and fat, and losing muscle while carrying excess visceral fat, sarcopenic obesity, carries dramatically higher mortality risk than either condition in isolation, making resistance training alongside any weight-management effort a priority rather than an optional add-on.
References
Every numbered citation in this entry links here. Each reference links out to the primary source.
-
[1]
Sarcopenia alone HR 1.93 for composite outcome; sarcopenic obesity HR 6.74; all-cause mortality 8.48x higher in sarcopenic patients (56.3 vs 6.9 per 1,000 person-years).
-
[2]
Men: visceral fat OR 1.99 per 100g for all-cause mortality; women: sarcopenia OR 62.88 for all-cause mortality, OR 74.54 for cardiovascular mortality; sex-specific effects.
-
[3]
Sarcopenic obesity and health outcomes: An umbrella review of systematic reviews with meta-analysis Tier 2
Sarcopenic obesity HR 1.63 (95% CI 1.01-2.62) for cardiovascular mortality; certainty of evidence graded very low due to inconsistency across studies.
-
[4]
DXA-derived body composition and mortality risk in older adults Tier 3
Methodological review establishing DXA as the clinical reference standard for fat/lean/bone mass quantification in aging research.
-
[5]
Muscle mass, sarcopenia, and mortality in aging populations: cohort review Tier 3
Review contextualizing lean muscle mass preservation as a modifiable target for reducing age-related mortality risk.
-
[6]
Blueprint Biomarkers testing page Tier 4
General Blueprint panel page confirming body composition markers (DXA fat/muscle mass) are part of the tracked 100+ biomarker suite.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.
Follow Body Composition (Fat Mass, Lean Mass, Visceral Fat) through the chain: the mechanism that moves it, the molecule that targets it, the products that dose it, and the trials that tested it.
See Body Composition (Fat Mass, Lean Mass, Visceral Fat) on the Longevity Map →